Pages that link to "Q35211545"
Jump to navigation
Jump to search
The following pages link to Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable (Q35211545):
Displaying 7 items.
- Patient Engagement Practices in Clinical Research among Patient Groups, Industry, and Academia in the United States: A Survey (Q28550268) (← links)
- Different PD-MCI criteria and risk of dementia in Parkinson's disease: 4-year longitudinal study (Q33917294) (← links)
- The Everyday Cognition Scale in Parkinson's disease. (Q38697591) (← links)
- Diminished EEG habituation to novel events effectively classifies Parkinson's patients (Q48509840) (← links)
- Cognitive impairment in Parkinson's disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. (Q55451028) (← links)
- Frontal atrophy as a marker for dementia conversion in Parkinson's disease with mild cognitive impairment (Q64765351) (← links)
- A Randomized Clinical Trial of Atomoxetine for Mild Cognitive Impairment in Parkinson's Disease (Q92582730) (← links)